These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29886532)

  • 1. Purification and Fibrillation of Recombinant Human Amyloid-β, Prion Protein, and Tau Under Native Conditions.
    Sandberg A; Nyström S
    Methods Mol Biol; 2018; 1779():147-166. PubMed ID: 29886532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prion Diseases: A Unique Transmissible Agent or a Model for Neurodegenerative Diseases?
    Ritchie DL; Barria MA
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33540845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases.
    Sarnataro D
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloidogenesis of Tau protein.
    Nizynski B; Dzwolak W; Nieznanski K
    Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Million-fold sensitivity enhancement in proteopathic seed amplification assays for biospecimens by Hofmeister ion comparisons.
    Metrick MA; do Carmo Ferreira N; Saijo E; Hughson AG; Kraus A; Orrú C; Miller MW; Zanusso G; Ghetti B; Vendruscolo M; Caughey B
    Proc Natl Acad Sci U S A; 2019 Nov; 116(46):23029-23039. PubMed ID: 31641070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroinflammation and common mechanism in Alzheimer's disease and prion amyloidosis: amyloid-associated proteins, neuroinflammation and neurofibrillary degeneration.
    Rozemuller AJ; Jansen C; Carrano A; van Haastert ES; Hondius D; van der Vies SM; Hoozemans JJ
    Neurodegener Dis; 2012; 10(1-4):301-4. PubMed ID: 22398730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One or more β-amyloid(s)? New insights into the prion-like nature of Alzheimer's disease.
    Catania M; Di Fede G
    Prog Mol Biol Transl Sci; 2020; 175():213-237. PubMed ID: 32958234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fundamentals of cross-seeding of amyloid proteins: an introduction.
    Ren B; Zhang Y; Zhang M; Liu Y; Zhang D; Gong X; Feng Z; Tang J; Chang Y; Zheng J
    J Mater Chem B; 2019 Dec; 7(46):7267-7282. PubMed ID: 31647489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes.
    Mailliot C; Sergeant N; Bussière T; Caillet-Boudin ML; Delacourte A; Buée L
    FEBS Lett; 1998 Aug; 433(3):201-4. PubMed ID: 9744794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases.
    Walker LC
    Annu Rev Genet; 2016 Nov; 50():329-346. PubMed ID: 27893962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Tau and α-Synuclein Pathology in the Visual System.
    Rahimi J; Milenkovic I; Kovacs GG
    J Parkinsons Dis; 2015; 5(2):333-40. PubMed ID: 25737267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and Fibrillation of Full-Length Recombinant PrP.
    Makarava N; Savtchenko R; Baskakov IV
    Methods Mol Biol; 2017; 1658():3-22. PubMed ID: 28861778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-β Peptide Induces Prion Protein Amyloid Formation: Evidence for Its Widespread Amyloidogenic Effect.
    Honda R
    Angew Chem Int Ed Engl; 2018 May; 57(21):6086-6089. PubMed ID: 29645399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases.
    Rohan Z; Smetakova M; Kukal J; Rusina R; Matej R
    BMC Neurol; 2015 Mar; 15():50. PubMed ID: 25886404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease.
    Debatin L; Streffer J; Geissen M; Matschke J; Aguzzi A; Glatzel M
    Neurodegener Dis; 2008; 5(6):347-54. PubMed ID: 18349519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prion-like Properties of Amyloid-beta Peptide and Tau: Is there Any Risk of Transmitting Alzheimer's Disease During Neurosurgical Interventions?
    Padilla-Zambrano HS; García-Ballestas E; Quiñones-Ossa GA; Sibaja-Perez AE; Agrawal A; Moscote-Salazar LR; Menéndez-González M
    Curr Alzheimer Res; 2020; 17(9):781-789. PubMed ID: 33280597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Creutzfeldt-Jakob disease unravel the mysteries of Alzheimer?
    Kovacs GG
    Prion; 2016 Sep; 10(5):369-376. PubMed ID: 27649940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies.
    López González I; Garcia-Esparcia P; Llorens F; Ferrer I
    Int J Mol Sci; 2016 Feb; 17(2):206. PubMed ID: 26861289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cellular prion protein in interneuronal amyloid transmission.
    Del Río JA; Ferrer I; Gavín R
    Prog Neurobiol; 2018; 165-167():87-102. PubMed ID: 29530723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.
    Abu Rumeileh S; Lattanzio F; Stanzani Maserati M; Rizzi R; Capellari S; Parchi P
    J Alzheimers Dis; 2017; 55(4):1471-1480. PubMed ID: 27886009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.